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Streptococcus pneumoniae and Neisseria meningitidis are the major causes of 
pneumonia and meningitis, respectively, worldwide. Capsular polysaccharide-protein 
vaccines (conjugate vaccines) provide protection against these diseases but not protection 
against infections caused by serotypes and serogroups not included in these vaccines. 
Proteins have been increasingly considered as antigens for vaccine development due to 
their more structurally conserved composition when compared to capsular 
polysaccharides. Proteins subunit vaccines are safe and protective; however, they have 
limitations such as serotype-dependent immunity, and low immunogenicity of the 
proteins, requiring adjuvant to be included in these formulations or delivery systems that 
enhance the desired immune response. In addition, complex production procedures are 
required, increasing production costs and therefore market prices making these vaccines 
inaccessible for many people affected by these diseases. Recently, bacterial storage 
polymer inclusions have been developed as protein antigen carriers. 
Polyhydroxyalkanoate, in particular 3-polyhydroxybutyrate (PHB) inclusions have been 
successfully bioengineered to display antigens from pathogens like Mycobacterium 
tuberculosis and Hepatitis C virus. These particulate vaccine candidates elicited both a 
Th1 and Th2 immunity patterns combined with a protective immune response against 
Mycobacterium bovis in mice.  
This thesis focuses on the study of polyhydroxybutyrate (PHB) beads properties as 
a carrier/delivery system engineered to display antigens from extracellular bacteria. The 
antigens Pneumococcal adhesin A, Pneumolysin (proteins) and 19F capsular 
polysaccharide (CPS) from Streptococcus pneumoniae, and Neisserial adhesin A, factor 
H binding protein (proteins) and serogroup C CPS from Neisseria meningitidis were 
displayed on the PHB bead surface. These antigenic proteins were produced as fusion 
 ii 
 
proteins on the PHB bead surface, while the CPS was covalently attached by chemical 
conjugation. Mice vaccinated with these PHB beads produced strong and antigen-specific 
antibody levels. In addition, splenocytes from the same mice generated both IL-17A and 
IFN-ɣ production.  
The antibodies elicited against antigenic pneumococcal proteins were able to 
recognise the same protein in the context of an Streptococcus pneumoniae whole cell 
lysate from more than six different strains, while antibodies produced after vaccination 
with 19F CPS conjugate to PHB showed high opsonophagocytic titers against the 
homologous strain. In the case of Neisseria meningitidis, bactericidal antibodies were 
elicited in mice vaccinated with PHB beads displaying proteinaceous and CPS antigens.  
Overall, this thesis shows that PHB as particulate vaccine candidate holds the 
promise of a broadly protective vaccine that can be produced cost-effectively for 
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